公开(公告)号：DE50110077D1

公开(公告)日：2006-07-20

申请号：DE50110077

申请日：2001-11-29

Applicant: BASF AG

Inventor： KLATT JOCHEN ,  NIEBEL MARKUS ,  PAUST JOACHIM

IPC: C07D339/04

Abstract: The present invention relates to a process for the preparation of R- and S-lipoic acid and R- and S-dihydrolipoic acid comprising (a) reaction of where MS is SO 2 -R' and R and R' independently of one another are C 1 -C 6 -alkyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkylalkyl, aryl or aralkyl, with sodium sulfide and sulfur in methanol. The invention especially relates to processes for preparing pure R- or S-dihydrolipoic acid, which is either used directly or processed further to give R- and S-lipoic acid. The process also serves for the production of pharmaceuticals. The present invention further relates to a solution of sodium sulfide trihydrate and sulfur in methanol, the sulfur being present in a molar excess over the sodium sulfide trihydrate, and a kit which comprises the solution according to the invention.

公开(公告)号：DE59902779D1

公开(公告)日：2002-10-24

申请号：DE59902779

申请日：1999-07-12

Applicant: BASF AG

Inventor： KLATT JOCHEN ,  NIEBEL MARKUS ,  PAUST JOACHIM ,  RIEGER JENS

IPC: A23L1/30 ,  A61K31/385 ,  C07B57/00 ,  C07D339/04

Abstract: In the 2 &THgr; diffractogram of an enantiomerically pure crystalline (R)- or (S)-lipoic acid, the most intense reflection line in the range from 13° to 30° is that at 2 &THgr;=23°.

公开(公告)号：DE50103029D1

公开(公告)日：2004-09-02

申请号：DE50103029

申请日：2001-09-11

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  BALDENIUS KAI-UWE ,  KLATT JOCHEN ,  SCHWEIKERT LONI

IPC: A61K31/381 ,  A23L1/30 ,  A61K31/00 ,  A61K31/202 ,  A61K31/385 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  A61P27/02

Abstract: The present invention relates to the use of lipoic acid, a physiologically acceptable derivative or salt thereof and one compound of the formula I H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH I in which n1, n2 have, independently of one another, the value of an integer from 3 to 9, n3 has the value of an integer from 2 to 6, and the number of carbon atoms is 18, 20 or 22, a physiologically acceptable derivative or salt thereof, for nutritional supplementation, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. Compositions having a corresponding active ingredient combination, and compositions in the form of commercial packs with corresponding combination products or single-drug products for combined use are also described.